Aldehyde dehydrogenase 1 expression is a predictor of poor prognosis in node-positive breast cancers: A long-term follow-up study

Histopathology

Volumn 58, Issue 4, 2011, Pages 608-616

  Yoshioka, Takako ^a   Umekita, Yoshihisa ^a   Ohi, Yasuyo ^b   Souda, Masakazu ^a   Sagara, Yoshiatsu ^b   Sagara, Yasuaki ^b   Sagara, Yoshiaki ^b   Rai, Yoshiaki ^b   Tanimoto, Akihide ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

^b SAGARA HOSPITAL   (Japan)

Author keywords

ALDH1; Breast cancer; Immunohistochemistry

Indexed keywords

ALDEHYDE DEHYDROGENASE; ALDEHYDE DEHYDROGENASE ISOENZYME 1; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PARAFFIN; PROGESTERONE RECEPTOR; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER RELAPSE; CANCER SIZE; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; INVASIVE CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CONFIDENCE INTERVALS; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; ISOENZYMES; LYMPHATIC METASTASIS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; RETINAL DEHYDROGENASE; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 79952711817     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2011.03781.x     Document Type: Article

References (19)

1. Lapidot T, Sirard C, Vormoor J et al. A cell initiating human acute myeloid leukemia after transplantation into SCID mice. Nature 1994; 367; 645-648.
2. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc. Natl Acad. Sci. USA 2003; 100; 3983-3988.
3. Magni M, Shammah S, Schiro R, Mellado W, Dalla-Fevera R, Gianni AM. Induction of cyclophosphamide-resistance by aldehyde-dehydrogenase gene transfer. Blood 1996; 87; 1097-1103.
4. Sophos NA, Vasiliou V. Aldehyde dehydrogenase gene superfamily: the 2002 update. Chem. Biol. Interact. 2003; 143-144; 5-22.
5. Duester G, Mic FA, Molotkov A. Cytosolic retinoid dehydrogenases govern ubiquitous metabolism of retinol to retinaldehydes followed by tissue-specific metabolism to retinoic acid. Chem. Biol. Interact. 2003; 143-144; 201-210.
6. Ginestier C, Hur MH, Charafe-Jauffret E et al. ALDH1 is a marker of normal and human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007; 1; 555-567.
7. Morimoto K, Kim SJ, Tanei T et al. Stem cell marker aldehyde dehydrogenase 1-positive breast cancers are characterized by negative estrogen receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression. Cancer Sci. 2009; 100; 1062-1068.
8. Resetkova E, Reis-Filho JS, Jain RK et al. Prognostic impact of ALDH1 in breast cancer: a story of stem cells and tumor microenvironment. Breast Cancer Res. Treat. 2010; 123; 109-111.
9. Tavassoli FA, Devilee P eds. World Health Organization classification of tumours. Pathology and genetics of tumours of the breast and female genital organs. Lyon: IARC Press, 2003; 10-11.
10. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19; 403-410.
11. McGuire WL, De La Garza M, Chammnes GC. Evaluation of estrogen receptor assays in human breast cancer tissue. Cancer Res. 1977; 37; 637-639.
12. Silverstein MJ, Poller DN, Waisman JR et al. Prognostic classification of breast ductal carcinoma-in-situ. Lancet 1995; 345; 1154-1157.
13. Umekita Y, Souda M, Ohi Y et al. Expression of wild-type estrogen receptor β protein in human breast cancer: specific correlation with HER2/neu overexpression. Pathol. Int. 2006; 56; 423-427.
14. Umemura S, Kurosumi M, Moriya T et al. Immunohistochemical evaluation for hormone receptors in breast cancer: a practically useful evaluation system and handling protocol. Breast Cancer 2006; 13; 232-235.
15. Wolff AC, Hammond EH, Schwartz JN et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol. 2007; 25; 118-145.
16. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 1958; 53; 457-481.
17. Cox DR. Regression models and life-tables. J. R. Stat. Soc. 1972; 34; 187-220.
18. Tanei T, Morimoto K, Shimazu K et al. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential paclitaxel and epirubicin-based chemotherapy for breast cancers. Clin. Cancer Res. 2009; 15; 4234-4241.
19. Korkaya H, Paulson A, Iovino F, Wicha MS. HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene 2008; 27; 6120-6130.